Health ❯Nutrition

Hormones

Gerontology Hormones Research Studies Molecular Biology Preventive Medicine Chronic Diseases Obesity Pharmaceuticals Pharmacology Chronic Inflammation

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials